Current therapies for advanced melanoma include several clinically approved BRAF inhibitors (BRAFi; e.g., vemurafenib, dabrafenib) in combination with MEK inhibitors (MEKi; e.g., trametinib) [4,5]. Here, MAP2K7 is linked to melanoma.